tert-butyl ((1R,3R,4S)-4-amino-3-((tert-butylsulfonyl)methyl)cyclohexyl)carbamate | 848002-00-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物
• 英文名称: tert-butyl ((1R,3R,4S)-4-amino-3-((tert-butylsulfonyl)methyl)cyclohexyl)carbamate
• CAS: 848002-00-6
• 化学式: C₁₆H₃₂N₂O₄S
• 分子量: 348.507
• InChiKey: KFLFXRQYZIPAID-XQQFMLRXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.22
• 重原子数：
  23.0
• 可旋转键数：
  3.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  98.49
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  tert-butyl ((1R,3R,4S)-4-amino-3-((tert-butylsulfonyl)methyl)cyclohexyl)carbamate 在 N-甲基吗啉 、 palladium on activated charcoal 、 氢气 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 caesium carbonate 、 碘甲烷 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Alkylsulfone-containing trisubstituted cyclohexanes as potent and bioavailable chemokine receptor 2 (CCR2) antagonists

  摘要：

  We describe novel alkylsulfones as potent CCR2 antagonists with reduced hERG channel activity and improved pharmacokinetics over our previously described antagonists. Several of these new alkylsulfones have a profile that includes functional antagonism of CCR2, in vitro microsomal stability, and oral bioavailability. With this improved profile, we demonstrate that two of these antagonists, 2 and 12, are orally efficacious in an animal model of inflammatory recruitment. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.02.013
• 作为产物：
  描述：

  tert-butyl (1R,3R,4S)-4-benzyloxycarbonylamino-3-(tert-butylsulfonylmethyl)cyclohexylcarbamate 在 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 为溶剂， 生成 tert-butyl ((1R,3R,4S)-4-amino-3-((tert-butylsulfonyl)methyl)cyclohexyl)carbamate
  参考文献：
  名称：

  Alkylsulfone-containing trisubstituted cyclohexanes as potent and bioavailable chemokine receptor 2 (CCR2) antagonists

  摘要：

  We describe novel alkylsulfones as potent CCR2 antagonists with reduced hERG channel activity and improved pharmacokinetics over our previously described antagonists. Several of these new alkylsulfones have a profile that includes functional antagonism of CCR2, in vitro microsomal stability, and oral bioavailability. With this improved profile, we demonstrate that two of these antagonists, 2 and 12, are orally efficacious in an animal model of inflammatory recruitment. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.02.013